放射组学无创预测黑色素瘤脑转移患者BRAF突变状态
研究纳入两个大学脑肿瘤中心的59例黑色素瘤脑转移患者(第1组45例,第2组14例),术前增强MRI手动分割并提取放射组学特征,第1组用于模型训练与验证,第2组用于测试。第1组22/45例(49%)、第2组8/14例(57%)存在颅内BRAF V600E突变。基于六参数放射组学特征构建的线性支持向量机分类器在测试数据中ROC曲线下面积为0.92(敏感性83%,特异性88%)。
要点
- 放射组学分类器可无创预测黑色素瘤脑转移颅内BRAF V600E突变状态。
- 测试数据中ROC曲线下面积为0.92,敏感性83%,特异性88%。
- 第1组49%、第2组57%的患者存在颅内BRAF V600E突变。
核心结论
- 所开发的放射组学分类器能以高诊断性能无创预测黑色素瘤脑转移患者的颅内BRAF V600E突变状态。
研究设计与样本
- 研究纳入两个大学脑肿瘤中心的59例黑色素瘤脑转移患者(第1组45例,第2组14例),均接受肿瘤切除并随后进行颅内BRAF突变状态的基因分析。
- 术前增强MRI被手动分割并分析,第1组用于模型训练与验证,第2组用于模型测试。
- 在放射组学特征提取后、特征选择前进行重测分析以识别稳健特征,最终将表现最佳的放射组学模型应用于测试数据,并使用受试者工作特征(ROC)分析评估诊断性能。
主要发现
- 第1组45例患者中22例(49%)存在颅内BRAF V600E突变,第2组14例患者中8例(57%)存在颅内BRAF V600E突变。
- 使用六参数放射组学特征的线性支持向量机分类器在测试数据中产生的ROC曲线下面积为0.92(敏感性83%,特异性88%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The BRAF V600E mutation is present in approximately 50% of patients with melanoma brain metastases and an important prerequisite for response to targeted therapies, particularly BRAF inhibitors. As heterogeneity in terms of BRAF mutation status may occur in melanoma patients, a wild-type extracranial primary tumor does not necessarily rule out a targetable mutation in brain metastases using BRAF inhibitors. We evaluated the potential of MRI radiomics for a noninvasive prediction of the intracranial BRAF mutation status. METHODS: Fifty-nine patients with melanoma brain metastases from two university brain tumor centers (group 1, 45 patients; group 2, 14 patients) underwent tumor resection with subsequent genetic analysis of the intracranial BRAF mutation status. Preoperative contrast-enhanced MRI was manually segmented and analyzed. Group 1 was used for model training and validation, group 2 for model testing. After radiomics feature extraction, a test-retest analysis was performed to identify robust features prior to feature selection. Finally, the best performing radiomics model was applied to the test data. Diagnostic performances were evaluated using receiver operating characteristic (ROC) analyses. RESULTS: Twenty-two of 45 patients (49%) in group 1, and 8 of 14 patients (57%) in group 2 had an intracranial BRAF V600E mutation. A linear support vector machine classifier using a six-parameter radiomics signature yielded an area under the ROC curve of 0.92 (sensitivity, 83%; specificity, 88%) in the test data. CONCLUSIONS: The developed radiomics classifier allows a noninvasive prediction of the intracranial BRAF V600E mutation status in patients with melanoma brain metastases with high diagnostic performance.
引用
- Meißner AK, Gutsche R, Galldiks N, et al. Radiomics for the noninvasive prediction of the BRAF mutation status in patients with melanoma brain metastases. Neuro Oncol. 2022. PMID: 34935978. doi:10.1093/neuonc/noab294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。